您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Mito-apocynin(C11)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Mito-apocynin(C11)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Mito-apocynin(C11)图片
规格:98%
分子量:663.62
包装与价格:
包装价格(元)
50mg电议
100mg电议

产品介绍
Mito-apocynin(C11),基于三苯基膦酸(TPP+)的线粒体靶向化合物,并具有口服性的化合物。Mito-apocynin(C11)由Apocynin部分与TPP+阳离子结合而合成。Mito-apocynin(C11)选择性靶向线粒体,具有神经保护作用。Mito-apocynin(C11)可预防嗅觉减退,纠正运动功能的缺陷。
货号:ajcx31074
CAS:1254044-38-6
分子式:C37H44BrO4P
分子量:663.62
溶解度:DMSO: 100 mg/mL (150.69 mM)
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Mito-apocynin (C11), an orally active mitochondria-targeted triphenylphosphonium (TPP)-based compound, is synthesized by conjugating the Apocynin moiety with a TPP+ cation. Mito-apocynin (C11) selectively targets mitochondria, and shows neuroprotective effect. Mito-apocynin (C11) prevents hyposmia and corrects deficits in motor function[1].


Mito-apocynin-C11 (3 mg/kg; oral gavage; 3x/wk from 3 months of age until 15 months) markedly improves the coordinated motor function and olfactory function in LRRK2R1441G mice[1]. Animal Model: LRRK2R1441G mice[1]

[1]. Dranka BP, et al. A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse model of Parkinson's disease. Neurosci Lett. 2014 Nov 7;583:159-64.